Answered step by step
Verified Expert Solution
Link Copied!

Question

1 Approved Answer

Megafund financing methods for funding early-stage translational research often require billions of dollars in capital to diversify idiosyncratic scientific and clinical risk enough to attract

Megafund financing methods for funding early-stage translational research often require billions of dollars in capital to diversify idiosyncratic scientific and clinical risk enough to attract private-sector capital. In this problem set we apply this financing method to orphan drug development, where development costs, failure rates, and correlations are low, and therefore the amount of capital required to de-risk these portfolios is much lower.
Consider a portfolio of 8 preclinical orphan drug compounds each initially acquired and developed using US$25 million of capital. Assume this capital is used to first purchase and then develop the compounds, with excess capital not currently deployed earning a 0% return in cash. For simplicity, also assume that compounds are sold once they (successfully) complete the preclinical phase. We will perform a statistical analysis to estimate the expected return of this investment over the initial preclinical research phase.
Problem 1
Assuming average annual sales of US$300 million, a 10% cost of capital, a competition-free marketing period of 12 years, and profit margin of 25%, estimate the net present value of an orphan drugs profits over its competition-free lifespan at the moment of product launch. Assume the first cash flow occurs 1 year after launch.
$ million
Problem 2
Using the estimates for clinical trial costs, success rates, and duration in the table below, estimate the expected value of an orphan drug at the beginning of the following phases. Assume that the effective annual cost of capital for preclincal research, Phase 1, Phase 2, Phase 3, and NDA review are 30%, 30%, 30%, 25%, and 15%, respectively, and that clinical trial costs are incurred at the beginning of each phase.
Phase
Cost (US$ million) Probability of Success Duration (years)
Preclinical 5 69% 1.00
Phase 1 5 84% 1.66
Phase 2 8 53% 2.09
Phase 3 43 74% 2.15
NDA 96% 0.80
NDA:
$ million
Phase III:
$ million
Phase II:
$ million
Phase I:
$ million
Preclinical:
$ million
Problem 3
At the end of the preclinical research phase, what is the expected value and standard deviation of the return on the US$25 million of capital invested in a single preclinical orphan drug compound. Assume that capital held in cash earns no interest. (Note: Your answer should be a number in percentage form. Do not enter '%'.)
E[]= %
SD()= %
Please ... Somebody Help me ?
tks

Step by Step Solution

There are 3 Steps involved in it

Step: 1

blur-text-image

Get Instant Access to Expert-Tailored Solutions

See step-by-step solutions with expert insights and AI powered tools for academic success

Step: 2

blur-text-image

Step: 3

blur-text-image

Ace Your Homework with AI

Get the answers you need in no time with our AI-driven, step-by-step assistance

Get Started

Recommended Textbook for

Cost Of Capital Applications And Examples

Authors: Shannon P. Pratt, Roger J. Grabowski, Richard A. Brealey

5th Edition

1118555805, 9781118555804

More Books

Students also viewed these Finance questions

Question

Give another example of adverse selection.

Answered: 1 week ago